Empagliflozin Disease Interactions
There are 3 disease interactions with empagliflozin:
Sglt-2 Inhibitors (Includes Empagliflozin) ↔ Renal Dysfunction
Severe Potential Hazard, Moderate plausibility
Applies to: Renal Dysfunction
The glucose lowering effects of SGLT-2 inhibitors is decreased in patients with worsening renal function. Additionally, SGLT-2 inhibitors increase serum creatinine and decrease eGFR. The elderly and patients with moderate renal impairment are at increased risk of further renal dysfunction. Renal function should be evaluated before treatment initiation and monitored regularly in these patients. The use of SGLT-2 inhibitors in patients with severe renal impairment, end stage renal dysfunction (ESRD), or undergoing dialysis is contraindicated. Based on its mechanism of action, SGLT-2 inhibitors are not expected to be effective in patients with this level of renal dysfunction.
Sglt-2 Inhibitors (Includes Empagliflozin) ↔ Hyperlipidemia
Moderate Potential Hazard, Moderate plausibility
Applies to: Hyperlipidemia
There have been reports of dose-related increases in LDL cholesterol with the use of SGLT-2 inhibitors. Cholesterol levels should be monitored before and during treatment and appropriate therapy should be initiated if needed.
Sglt-2 Inhibitors (Includes Empagliflozin) ↔ Hypotension
Moderate Potential Hazard, Moderate plausibility
Applies to: Renal Dysfunction, Hypotension
SGLT-2 inhibitors cause intravascular volume contraction and symptomatic hypotension may occur after treatment initiation especially in the elderly, in patients with impaired renal function, low systolic blood pressure, or using diuretics . Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.
empagliflozin drug Interactions
There are 744 drug interactions with empagliflozin
empagliflozin alcohol/food Interactions
There are 2 alcohol/food interactions with empagliflozin
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
